Shots:
- Innovent has reported the P-III (G-HOPE-001) of arcotatug tavatecan (IBI343/TAK-921) vs investigator-selected therapy in pts with Claudin 18.2 positive, locally advanced unresectable or metastatic G/GEJA who have received ≥2 prior therapies
- Trial met its 1EP of improved PFS in the interim analysis & showed a favorable safety profile; data to be published in future academic conferences or journals
- Based on the clinical data, Innovent has submitted the NDA for arcotatug tavatecan to the NMPA for the same indication, which has been accepted with priority review
Ref: PRnewswire | Image: Innovent| Press Release
Related News: Pfizer and Innovent Biologics Partner to Accelerate 12 Oncology Programs in a Deal Valued at ~$10.5B
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
